Seelos Therapeutics

13:20 28 May 2020

Seelos Therapeutics initiates preclinical study of SLS-004 in Parkinson's disease

Seelos Therapeutics Inc (NASDAQ:SEEL) said it has initiated a preclinical study of SLS-004 in Parkinson's disease (PD) through an all-in-one lentiviral vector targeting the synuclein alpha (SNCA) gene.

Seelos said it is constructing a bimodular viral system harboring an endogenous alpha-synuclein (?-synuclein) transgene and inducible regulated repressive CRISPR/Cas9-unit to achieve constitutive activation and inducible suppression of PD-related pathologies.

READ: Seelos Therapeutics to host key opinion leader call to discuss unmet medical needs in suicide and depression
?-synuclein is a protein of interest to Parkinson's researchers because it is a major constituent of Lewy bodies and Lewy neurites, protein clumps that are the pathological hallmark of synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).

The company said that it had been previously shown that enrichment in DNA methylation at intron 1 of the ?-synuclein gene SNCA, through SLS-004, facilitated "robust and precise repression of SNCA expression". The SNCA gene has been implicated as a highly significant risk factor for PD.

In a statement, Seelos chairman and chief executive Raj Mehra said: "There has been a high level of interest in the alpha-synuclein approach to Parkinson's and beginning further work on our first gene therapy program is exciting. Initiating this preclinical study earlier than expected is also very significant."

Contact the author at calum@proactiveinvestors.com

Follow him on Twitter @Cal_Proac

Price:	1.01
Market Cap:	$53.96 m

1 Year Share Price Graph



Share Information

Code:		SEEL
Listing:		NASDAQ
52 week	**High**	**Low**
	1.705	**0.42**
Sector:		**Pharma & Biotech**
Website:		**seelostherapeutics.com**

Company Synopsis:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.

action@proactiveinvestors.com

security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars ($25,000).